Total Payments
$715,210
2024 Payments
$32,069
Companies
37
Transactions
834
Medicare Patients
3,127
Medicare Billing
$470,138
Payment Breakdown by Category
Other$441,336 (61.7%)
Consulting$196,741 (27.5%)
Travel$63,876 (8.9%)
Food & Beverage$12,585 (1.8%)
Education$672.28 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $440,336 | 189 | 61.6% |
| Consulting Fee | $196,741 | 77 | 27.5% |
| Travel and Lodging | $63,876 | 235 | 8.9% |
| Food and Beverage | $12,585 | 327 | 1.8% |
| Honoraria | $1,000 | 1 | 0.1% |
| Education | $672.28 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $147,517 | 229 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $143,350 | 114 | $0 (2024) |
| Merck Sharp & Dohme LLC | $113,631 | 127 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $102,447 | 81 | $0 (2024) |
| Foundation Medicine, Inc. | $81,859 | 35 | $0 (2023) |
| Eisai Inc. | $79,420 | 87 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $9,464 | 24 | $0 (2024) |
| Gilead Sciences, Inc. | $8,047 | 7 | $0 (2021) |
| Amgen Inc. | $5,874 | 4 | $0 (2024) |
| Eli Lilly and Company | $5,260 | 15 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,069 | 31 | JAZZ PHARMACEUTICALS INC. ($22,246) |
| 2023 | $51,293 | 42 | Jazz Pharmaceuticals Inc. ($38,288) |
| 2022 | $42,935 | 28 | Foundation Medicine, Inc. ($42,120) |
| 2021 | $114,251 | 81 | JAZZ PHARMACEUTICALS INC. ($38,378) |
| 2020 | $117,953 | 146 | Takeda Pharmaceuticals U.S.A., Inc. ($43,745) |
| 2019 | $230,782 | 292 | Lilly USA, LLC ($94,453) |
| 2018 | $80,068 | 121 | Takeda Pharmaceuticals U.S.A., Inc. ($27,598) |
| 2017 | $45,858 | 93 | Merck Sharp & Dohme Corporation ($32,825) |
All Payment Transactions
834 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $780.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/25/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,894.00 | General |
| 11/21/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $535.93 | General |
| 11/20/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $145.74 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $107.63 | General |
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.98 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,298.00 | General |
| 09/23/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,460.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/18/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $101.30 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/07/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $432.35 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/07/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $201.98 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $113.13 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $23.10 | General |
| Category: Oncology | ||||||
| 07/03/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $53.44 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/03/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/03/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $42.86 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/01/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,240.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/20/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $369.51 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/06/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $144.29 | General |
| Category: Oncology | ||||||
| 05/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.91 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,204 | 11,459 | $623,796 | $183,969 |
| 2022 | 38 | 1,283 | 24,683 | $746,958 | $196,876 |
| 2021 | 10 | 346 | 4,989 | $167,567 | $43,334 |
| 2020 | 5 | 294 | 622 | $297,469 | $45,959 |
Total Patients
3,127
Total Services
41,753
Medicare Billing
$470,138
Procedure Codes
83
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 192 | 585 | $237,485 | $85,160 | 35.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 87 | 87 | $49,978 | $16,000 | 32.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 41 | 134 | $73,700 | $15,647 | 21.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 97 | 99 | $54,360 | $14,450 | 26.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 109 | 217 | $43,327 | $14,450 | 33.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 78 | $23,856 | $8,323 | 34.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 55 | 81 | $23,428 | $8,112 | 34.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $19,525 | $5,682 | 29.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 36 | $6,660 | $2,052 | 30.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 15 | 34 | $9,350 | $1,948 | 20.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $5,666 | $1,643 | 29.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 117 | 183 | $10,980 | $1,537 | 14.0% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 14 | 31 | $7,285 | $1,525 | 20.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 36 | 99 | $7,108 | $1,213 | 17.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 103 | 157 | $5,024 | $1,195 | 23.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 18 | 42 | $4,620 | $1,070 | 23.2% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 12 | 5,100 | $5,100 | $858.73 | 16.8% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 21 | 60 | $3,600 | $673.40 | 18.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 14 | 42 | $3,150 | $571.98 | 18.2% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 13 | 3,900 | $19,500 | $505.59 | 2.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 12 | 14 | $2,030 | $462.14 | 22.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 14 | 23 | $1,380 | $412.87 | 29.9% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 22 | 26 | $702.00 | $164.84 | 23.5% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 14 | 62 | $2,790 | $125.15 | 4.5% |
| 85007 | Microscopic examination for white blood cells with manual cell count | Office | 2023 | 22 | 26 | $364.00 | $96.72 | 26.6% |
About Dr. Shayma Kazmi, MD
Dr. Shayma Kazmi, MD is a Hematology & Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1801919550.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shayma Kazmi, MD has received a total of $715,210 in payments from pharmaceutical and medical device companies, with $32,069 received in 2024. These payments were reported across 834 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($440,336).
As a Medicare-enrolled provider, Kazmi has provided services to 3,127 Medicare beneficiaries, totaling 41,753 services with total Medicare billing of $470,138. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Philadelphia, PA
- Active Since 04/09/2007
- Last Updated 05/11/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801919550
Products in Payments
- VERZENIO (Drug) $131,004
- ALUNBRIG (Drug) $127,841
- ZEPZELCA (Drug) $102,432
- KEYTRUDA (Biological) $89,434
- FOUNDATIONONE CDX (Device) $80,730
- Halaven (Drug) $75,890
- Trodelvy (Drug) $10,847
- EXKIVITY (Drug) $3,606
- Lenvima (Drug) $3,530
- ONTRUZANT (Biological) $2,750
- Vitrakvi (Drug) $2,548
- TAGRISSO (Drug) $2,167
- LIBTAYO (Biological) $1,592
- FOUNDATIONONE LIQUID (Device) $1,049
- Tepmetko (Drug) $500.00
- Optune (Device) $338.61
- KISQALI (Drug) $184.37
- IMFINZI (Drug) $146.69
- OPDIVO (Biological) $133.79
- Nubeqa (Drug) $124.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Philadelphia
Charu Aggarwal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $510,275
Hematology & Oncology $510,275
Dr. Catherine Lai, M.d., M.p.h, M.D., M.P.H
Hematology & Oncology — Payments: $249,951
Hematology & Oncology $249,951
Dr. Martin Edelman, M.d, M.D
Hematology & Oncology — Payments: $207,464
Hematology & Oncology $207,464
Keith Pratz, M.d, M.D
Hematology & Oncology — Payments: $175,955
Hematology & Oncology $175,955
David Porter, Md, MD
Hematology & Oncology — Payments: $173,636
Hematology & Oncology $173,636
Marcela Maus, Md, MD
Hematology & Oncology — Payments: $159,783
Hematology & Oncology $159,783